

James A. FitzPatrick
Nuclear Power Plant
P.O. Box 41
Lycoming, New York 13093
315 342-3840



Harry P. Salmon, Jr.
Resident Manager

May 30, 1995
JAFP-95-0259

United States Nuclear Regulatory Commission
Document Control Desk
Mail Station P1-137
Washington, D.C. 20555

Subject: Docket No. 50-333
10 CFR 26 - Appendix A, "Guidelines For Drug And
Alcohol Testing Programs", Section 2.8 (e) (4)

Dear Sir:

This report is provided to you in accordance with 10 CFR 26 -
Appendix A, "Quality Assurance and Quality Control"
requirements.

On May 1, 1995, the Fitness For Duty Administrator at the
James A. FitzPatrick Nuclear Power Plant (JAFNPP) identified
a urine blind test specimen (BTS) test result that had been
incorrectly reported (positive opiate BTS reported as
negative) by the facilities H.H.S. testing laboratory. The
Power Authority initiated an investigation that included:
contacting the testing laboratory to inform them of the
condition, and contacting the facilities which supplied and
manufactured the controlled urine test sample to verify the
specimen concentrations.

The following is a sequence of events which lead to the
finding:

January 14, 1995, Specimen Number T61513 was prepared by
Forensic Control Company. The Forensic Control laboratory
prepares the BTS for Bensinger, DuPont and Associates, the
company contracted by JAFNPP to supply BTS samples.

SAMPLE COMPOSITION:

Matrix - Human urine,

Identity and Concentration of Opiates - Morphine - 450 ng/ml
- Codeine - 600 ng/ml

April 3, 1995, Specimen Number T61513 was shipped from
Forensic Control Company laboratory to JAFNPP.

9506080026 950530
PDR ADOCK 05000333
F PDR

A022
11

UNITED STATES NUCLEAR REGULATORY COMMISSION
DOCUMENT CONTROL DESK

SUBJECT: DOCKET NO. 50-333

10 CFR 26 - APPENDIX A, "GUIDELINES FOR DRUG AND
ALCOHOL TESTING PROGRAMS", SECTION 2.8 (e) (4)

PAGE -2-

April 4, 1995, Specimen Number T61513 was entered into normal specimen shipment to MetPath Incorporated, JAFNPP's H.H.S. laboratory.

April 6, 1995, Specimen Number T61513 received by MetPath Inc.

April 12, 1995, MetPath Inc. completes sample analysis. Specimen Number T61513 reported as negative.

April 12, 1995, the negative sample results were reported to Industrial Medical Associates of Syracuse, N.Y., JAFNPP Medical Review Officer.

May 1, 1995, the Fitness For Duty Administrator at JAFNPP received the report from Industrial Medical Associates for Specimen Number T61513 and identified the "False Negative" test specimen results.

IMMEDIATE CORRECTIVE ACTION:

May 1, 1995, Bensinger, DuPont and Associates, and Industrial Medical Associates were notified by the JAFNPP Fitness For Duty Administrator of the reported "False Negative" results of the sample specimen. On May 2, 1995, notification was made to Metpath, Inc.

An evaluation and reviews of the testing process were conducted to determine the cause(s) for the identified condition. It appears that the matrix of this urine specimen interfered with the testing and caused an unacceptable ion chromatography which under federal regulations necessitates the reporting of a negative result.

A review by Bensinger, DuPont and Associates of MetPath Inc.'s overall "False Negative" rate for the testing of spiked specimens over the past three months reflected no negative patterns. Therefore, Bensinger, DuPont, and Associates concluded that an isolated "False Negative" did not signal a deficiency in the laboratory's analysis program.

UNITED STATES NUCLEAR REGULATORY COMMISSION
DOCUMENT CONTROL DESK

SUBJECT: DOCKET NO. 50-333
10 CFR 26 - APPENDIX A, "GUIDELINES FOR DRUG AND
ALCOHOL TESTING PROGRAMS", SECTION 2.8 (e) (4)

PAGE -3-

Additionally, a letter was issued by the Power Authority to Industrial Medical Associates of Syracuse requesting that laboratory results be submitted to the Fitness For Duty Administrator in a more timely matter.


ATTACHMENTS

Attachment 1 contains Bensinger, DuPont and Associates summary of BTS Specimen Number T61513 supplied to MetPath, Inc. testing laboratory.

Attachment 2 contain MetPath, Inc. summary of the testing evolutions performed by their laboratory on BTS Specimen Number T61513.

If you have questions concerning this issue, please contact Mr. Gordon Brownell of my staff at (315) 349-6360.

Very truly yours,



HARRY P. SALMON, JR.

HPS:GJB:las
Attachments (2)

cc: USNRC, Region I
USNRC Resident Inspector
USNRC Project Directorate

BENSINGER, DUPONT & ASSOCIATES
11300 Rockville Pike, Suite 713
Rockville, MD 20852

(301) 292-4520

(301) 816-1085

Litigation Summary

New York Power Authority-Fitzpatrick

Kit#: 3782

Date Shipped: April 3, 1995

Social Security #: 578-33-5496

Substance: Opiates

Originating Lab Result: Morphine = 520 ng/ml
Codeine = 670 ng/ml

Date Tested: 01/21/95

Reference Lab Result: Morphine = 495 ng/ml
Codeine = 628 ng/ml

Date Tested: 01/20/95

Batch #: OPT-013

Results for opiates for clients from the same batch:

Client #1	Opiates	Positive
Client #2	Opiates	Positive
Client #3	Opiates	Positive



MetPath Inc.
One Malcolm Avenue
Teterboro, New Jersey 07608-1070
201-393-5822
201-393-5000

John E. Heveran, Ph.D.
Corporate Director
Forensic Toxicology

• CORNING Clinical Laboratory

May 15, 1995

Carol A. Soucy, RN, C.O.H.N.
Occupational Health Nurse Administrator
New York Power Authority
P.O. Box 41
Lycoming, NY 13093

Dear Ms. Soucy:

In response to your letter, dated May 2, 1995, regarding the blind test specimen Number T61513, please note the following.

Specimen test T61513 was received by MetPath on 4/5/95 and screened positive for opiates on 4/6/95.

On 4/6/95, the specimen was extracted for morphine and codeine for GC/MS confirmation. However, due to an unresolved peak in the second qualifying ion for morphine and out of range ion ratios for codeine, the specimen data did not meet all of protocol criteria for confirmation of either morphine or codeine.

The specimen was repeated on dilution to minimize the urine interference and on 4/8/95, a new aliquot was re-extracted with dilution. The final concentrations recovered for morphine and codeine were equivalent to 466 and 643 ng/ml respectively. However, all the single ion chromatographic criteria could not be met. Due to the federal restriction, we could not report the final result with the message "WE ARE UNABLE TO OBTAIN SATISFACTORY RESULTS AFTER REPEAT ANALYSIS BY GC/MS". Consequently, the specimen was reported as negative.

Following receipt of the blind test specimen information provided to you by Dr. Richard H. Bucher of Bensinger, DuPont Associates, I shared with him the analytical results obtained by our lab for Specimen T61513. It is my understanding that he will be reviewing his records and will also be responding to you on the nature of the interfering substance.

It appears that the matrix of this urine specimen interfered with the testing and caused the unacceptable ion chromatography which under federal regulations necessitated the reporting of a negative result.

Sincerely,

A handwritten signature in dark ink, appearing to read "J. E. Heveran".
John E. Heveran, Ph.D.